Scholar Rock Holding (SRRK) Operating Leases (2019 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Operating Leases of $3.0 million for Q1 2026, down 62.25% year-over-year from $7.9 million in Q1 2025, and down 18.38% quarter-over-quarter from $3.7 million in Q4 2025.
Scholar Rock Holding (SRRK) Operating Leases (2019 - 2026) Analysis & Trends
Scholar Rock Holding's Operating Leases history runs 8 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Operating Leases fell 62.25% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 62.25% YoY), while the FY2025 annual figure was $3.7 million, down 60.29% from the prior year.
- Operating Leases for Q1 2026 stood at $3.0 million, down from $3.7 million in the prior quarter.
- The five-year high for Operating Leases was $17.7 million in Q1 2022, with the low at $2.4 million in Q1 2024.
- The 5-year median for Operating Leases is $8.2 million (2023), against an average of $8.7 million.
- The sharpest annual moves came in 2024 and 2025: Operating Leases plunged 75.95% in 2024, then soared 227.74% in 2025.
- Scholar Rock Holding's Operating Leases stood at $11.8 million in 2022, then plunged by 62.78% to $4.4 million in 2023, then soared by 109.61% to $9.2 million in 2024, then plunged by 60.29% to $3.7 million in 2025, then decreased by 18.38% to $3.0 million in 2026.
- Business Quant data shows SRRK's Operating Leases at $3.0 million in Q1 2026, $3.7 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 2.98 Mn |
| Dec 31, 2025 | 3.66 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Jun 30, 2025 | 6.56 Mn |
| Mar 31, 2025 | 7.91 Mn |
| Dec 31, 2024 | 9.21 Mn |
| Sep 30, 2024 | 10.47 Mn |
| Jun 30, 2024 | 11.77 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 4.39 Mn |
| Sep 30, 2023 | 6.34 Mn |
| Jun 30, 2023 | 8.23 Mn |
| Mar 31, 2023 | 10.03 Mn |
| Dec 31, 2022 | 11.80 Mn |
| Sep 30, 2022 | 13.54 Mn |
| Jun 30, 2022 | 15.65 Mn |
| Mar 31, 2022 | 17.67 Mn |
| Dec 31, 2021 | 19.65 Mn |
| Sep 30, 2021 | 21.60 Mn |